[Spontaneous remission of an amiodarone-induced pulmonary lesion].
Amiodarone is an effective class-III antiarrhythmic agent. However, during long term therapy 1-10% of patients develop severe adverse pulmonary reactions, which are potentially life threatening. We report the case of a patient who developed dyspnoea and extensive pulmonary infiltrates compatible with amiodarone-associated interstitial lung disease following 6 months of treatment with amdiodarone (300 mg daily) for atrial flutter. On discontinuation of amiodarone treatment the infiltrates impressively resolved almost completely within 8 weeks, without administration of corticosteroids.
Müller
M
M
Universitätsklinik für Innere Medizin III, Allgemeines Krankenhaus, Wien, Osterreich.
Schima
W
W
Weissel
M
M
D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging; D013902:Radiography, Thoracic; D012075:Remission, Spontaneous; D012307:Risk Factors
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone
Spontanremission einer Amiodaron-assoziierten Lungenparenchymschädigung.